Drug Trial Radar · NCT01942122
DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis
Last checked: Nov 19, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 2015
Primary completion
Feb 2021
Study completion Apr 2021
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Sep 13, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 3-arm, prospective, randomized, double-blind, and controlled study of DLBS1442 for the treatment of pain in patients suspected endometriosis. It is hypothesized that the reduction of the composite-pain intensity (as measured by VAS) from baseline to the end of study (week 8th) resulting from administration of DLBS1442, regardless of the dosage regimen, is significantly greater than that of Control. In addition, the administration of DLBS1442 at higher dose also results in significantly greater reduction than that of DLBS1442 at lower dose and of Control.
Conditions
- Endometrioma
- Visual Analogue Pain Scale: Moderate or Severe Pain
Interventions
DLBS1442 100Drug
Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Mefenamic acidDrug
Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
DLBS1442 200Drug
Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of intensity (VAS) of composite-painTime frame: Week 8
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynecology RSUP Fatmawati
Jakarta, Indonesia
Yasmin Clinic, Dr. Cipto Mangunkusumo Hospital (Kencana)
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Department of Obstetrics and Gynecology, RSUP Persahabatan
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.